Osteogenic peptides in bone regeneration

Current Pharmaceutical Design

Volumn 19, Issue 19, 2013, Pages 3391-3402

  Jabbari, Esmaiel ^a  

^a University of South Carolina   (United States)

Author keywords

Anabolic effect; Differentiation; Mineralization; Osteogenic marker expression; Osteogenic peptides; Osteoprogenitor cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HEPARIN; INTEGRIN; PEPTIDE;

ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE REGENERATION; CELL ADHESION; CELL DIFFERENTIATION; MINERALIZATION; ORTHOPEDIC IMPLANT; OSSIFICATION; OSTEOPROGENITOR CELL; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; REVIEW;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; DRUG DELIVERY SYSTEMS; HUMANS; OSTEOGENESIS; PEPTIDES;

EID: 84887329625     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319190006     Document Type: Article

References (102)

1. Rush SM. Bone graft substitutes: osteobiologics. Clin Podiatr Med Surg 2005; 22(4): 619-630.
2. Johnell O. The socio-economic burden of fractures: today and in the 21st century. Am J Med 1997; 103: 20S-25S.
3. Wayne DB, Trajtenberg CP, Hyman DJ. Tooth and periodontal disease: a review for the primary-care physician. South Med J 2001; 94(9): 925-32.
4. Black J. Making Broken Children Normal. Special report: gurus of medical tech. BusinessWeek 2003; 7: 30.
5. Niederwanger M, Urist MR. Demineralized bone matrix supplied by bone banks for a carrier of recombinant human bone morphogenetic protein (rhBMP-2): a substitute for autogeneic bone grafts. J Oral Implantol 1996; 22(3-4): 210-5.
6. Martin GJ, Jr., Boden SD, Marone MA, Marone MA, Moskovitz PA. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999; 12(3): 179-86.
7. Ohyama T, Kubo Y, Iwata H, Taki W. Beta-tricalcium phosphate combined with recombinant human bone morphogenetic protein-2: a substitute for autograft, used for packing interbody fusion cages in the canine lumbar spine. Neurol Med Chir (Tokyo) 2004; 44(5): 234-41.
8. Suh DY, Boden SD, Louis-Ugbo J, et al. Delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2) using a compression resistant matrix in posterolateral spine fusion in the rabbit and the non-human primate. Spine 2002; 27: 353-60.
9. Constantz BR, Ison IC, Fulmer MT, et al. Skeletal repair by in situ formation of the mineral phase of bone. Science 1995; 267(5205):1796-1799.
10. Kokubo S, Mochizuki M, Fukushima S, et al. Long-term stability of bone tissues induced by an osteoinductive biomaterial, recombinant human bone morphogenetic protein-2 and a biodegradable carrier. Biomaterials 2004; 25(10): 1795-803.
11. Kusumoto K, Bessho K, Fujimura K, Akioka J, Ogawa Y, Iizuka T. Prefabricated muscle flap including bone induced by recombinant human bone morphogenetic protein-2: an experimental study of ectopic osteoinduction in a rat latissimus dorsi muscle flap. Br J Plast Surg 1998; 51(4): 275-80.
12. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002; 27(16 Suppl 1): S66-85.
13. Gombotz WR, Pankey SC, Bouchard LS, Ranchalis J, Puolakkainen P. Controlled release of TGF-beta 1 from a biodegradable matrix for bone regeneration. J Biomater Sci Polym Ed 1993; 5(1-2): 49-63.
14. Downs EC, Robertson NE, Riss TL, Plunkett ML. Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. J Cell Physiol 1992; 152(2): 422-9.
15. Dogan AK, Gumusderelioglu M, Aksoz E. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo. J Biomed Mater Res B Appl Biomater 2005; 74(1): 504-10.
16. Meikle MC. On the transplantation, regeneration and induction of bone: the path to bone morphogenetic proteins and other skeletal growth factors. Surgeon 2007; 5(4): 232-43.
17. Mercado AE, Yang X, He X, Jabbari E. Effect of grafting BMP2 derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells J Tissue Eng Reg Med 2012
18. Behnam K, Phillips ML, Silva JD, Brochmann EJ, Duarte ME, Murray SS. BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/ non-collagenous protein. J Orthop Res 2005; 23(1): 175-80.
19. Lin X, Zamora PO, Albright S, Glass JD, Pena LA. Multidomain synthetic peptide B2A2 synergistically enhances BMP-2 in vitro. J Bone Miner Res 2005; 20(4): 693-703.
20. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim Biophys Acta 2003; 1651(1-2): 60-7.
21. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. J Biomed Mater Res A 2004; 70(1): 115-21.
22. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Accelerated bone repair with the use of a synthetic BMP-2-derived peptide and bone-marrow stromal cells. J Biomed Mater Res A 2005; 72(1): 77-82.
23. Yeh LC, Zavala MC, Lee JC. C-type natriuretic peptide enhances osteogenic protein-1-induced osteoblastic cell differentiation via Smad5 phosphorylation. J Cell Biochem 2006; 97(3): 494-500.
24. Gabet Y, Muller R, Regev E, et al. Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone 2004; 35(1): 65-73.
25. Sikavitsas VI, Temenoff JS, Mikos AG. Biomaterials and bone mechanotransduction. Biomaterials 2001; 22(19): 2581-93.
26. Robinson D, Bab I, Nevo Z. Osteogenic growth peptide regulates proliferation and osteogenic maturation of human and rabbit bonemarrow stromal cells. J Bone Mineral Res 1995; 10(5): 690-6.
27. Wozney JM. Overview of bone morphogenetic proteins. Spine 2002; 27(16 Suppl 1): S2-8.
28. Meyer RA, Jr., Meyer MH, Tenholder M, Wondracek S, Wasserman R, Garges P. Gene expression in older rats with delayed union of femoral fractures. J Bone Joint Surg Am 2003; 85-A(7): 1243-54.
29. Hillger F, Herr G, Rudolph R, Schwarz E. Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 2005; 280(15): 14974-80.
30. Balasundaram G, Yao C, Webster TJ. TiO2 nanotubes functionalized with regions of bone morphogenetic protein-2 increases osteoblast adhesion. J Biomed Mater Res A 2008; 84(2): 447-53.
31. Poh CK, Shi Z, Tan XW, et al. Cobalt chromium alloy with immobilized BMP peptide for enhanced bone growth. J Orthop Res 2011; 29(9): 1424-1430.
32. Shi X, Wang Y, Varshney RR, Rena L, Gong Y, Wang D-A. Microsphere-based drug releasing scaffolds for inducing osteogenesis of human mesenchymal stem cells in vitro. Eur J Pharm Sci 2010; 39: 59-67.
33. Owen TA, Aronow M, Shalhoub V, et al. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 1990; 143: 420-30.
34. Carpenter RS, Goodrich LR, Frisbie DD, Kisiday JD, Carbone B, McIlwraith CW. Osteoblastic differentiation of human and equine adult bone marrowderived mesenchymal stem cells when BMP-2 or BMP-7 homodimer genetic modification is compared to BMP-2/7 heterodimer genetic modification in the presence and absence of dexamethasone. J Orthop Res 2010; 28: 1330-7.
35. Kang Q, Sun MH, Cheng H, et al. Characterization of the distinct orthotopic boneforming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004; 11: 1312-8.
36. Bergeron E, Leblanc E, Drevelle O, et al. The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. Tissue Eng Part A 2012; 18(3-4): 342-52.
37. Beniash E, Simmer JP, Margolis HC. The effect of recombinant mouse amelogenins on the formation and organization of hydroxyapatite crystals in vitro. J Struct Biol 2005; 149: 182-90.
38. Warotayanont R, Frenkel B, Snead ML, Zhou Y. Leucine-rich amelogenin peptide induces osteogenesis by activation of the Wnt pathway. Biochem Biophys Res Commun 2009; 387(3): 558-63.
39. Wen X, Cawthorn WP, MacDougald OA, Stupp SI, Snead ML, Zhou Y. The influence of Leucine-rich amelogenin peptide on MSC fate by inducing Wnt10b expression. Biomaterials 2011; 32(27): 6478-86.
40. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 1999; 10: 79-98.
41. Santiago LY, Nowak RW, Rubin JP, Marra KG. Peptide-surface modification of poly(caprolactone) with laminin-derived sequences for adipose-derived stem cell applications. Biomaterials 2006; 27(15): 2962-9.
42. Ho MH, Hou LT, Tu CY, et al. Promotion of cell affinity of porous PLLA scaffolds by immobilization of RGD peptides via plasma treatment. Macromol Biosci 2006; 6(1): 90-8.
43. Hsu SH, Chang SH, Yen HJ, Whu SW, Tsai CL, Chen DC. Evaluation of biodegradable polyesters modified by type II collagen and Arg-Gly-Asp as tissue engineering scaffolding materials for cartilage regeneration. Artif Organs 2006; 30(1): 42-55.
44. Yang F, Williams CG, Wang DA, Lee H, Manson PN, Elisseeff J. The effect of incorporating RGD adhesive peptide in polyethylene glycol diacrylate hydrogel on osteogenesis of bone marrow stromal cells. Biomaterials 2005; 26(30): 5991-8.
45. Deng C, Tian HY, Zhang PB, Sun J, Chen XS, Jing XB. Synthesis and characterization of RGD peptide grafted poly(ethylene glycol)-b-poly(L-lactide)-b-poly(L-glutamic acid) triblock copolymer. Biomacromolecules 2006; 7(2): 590-6.
46. Jabbari E, He X, Valarmathi MT, Sarvestani AS, Xu W. Material properties and bone marrow stromal cells response to In situ crosslinkable RGD-functionlized lactide-co-glycolide scaffolds. J Biomed Mater Res A 2009; 89(1): 124-37.
47. Chen JS, Altman GH, Karageorgiou V, et al. Human bone marrow stromal cell and ligament fibroblast responses on RGD-modified silk fibers. Journal of Biomedical Materials Research Part A 2003; 67A(2): 559-70.
48. Shin H, Jo S, Mikos AG. Modulation of marrow stromal osteoblast adhesion on biomimetic oligo[poly(ethylene glycol) fumarate] hydrogels modified with Arg-Gly-Asp peptides and a poly(ethylene glycol) spacer. J Biomed Mater Res 2002; 61(2): 169-79.
49. Itoh D, Yoneda S, Kuroda S, et al. Enhancement of osteogenesis on hydroxyapatite surface coated with synthetic peptide (EEEEEEEPRGDT) in vitro. J Biomed Mater Res 2002; 62(2): 292-8.
50. Xiao G, Wang D, Benson MD, Karsenty G, Franceschi RT. Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem 1998; 273(49): 32988-94.
51. Fromigue O, Brun J, Marty C, Da Nascimento S, Sonnet P, Marie PJ. Peptide-based activation of alpha5 integrin for promoting osteogenesis. J Cell Biochem 2012; 113(9): 3029-38.
52. Hamidouche Z, Fromigue O, Ringe J, Haupl T, Vaudin P, Pages JC, et al. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci U S A 2009; 106(44): 18587-91.
53. Frith JE, Mills RJ, Hudson JE, Cooper-White JJ. Tailored integrinextracellular matrix interactions to direct human mesenchymal stem cell differentiation. Stem Cells Dev 2012; 21(13): 2442-56.
54. Agrawal V, Tottey S, Johnson SA, Freund J, Siu BF, Badylak SF. Recruitment of progenitor cells by an ECM cryptic peptide in a mouse model of digit amputation. Tissue Eng A 2011; 17(19-20): 2435-43.
55. Agrawal V, Kelly J, Tottey S, et al. An isolated cryptic peptide influences osteogenesis and bone remodeling in an adult mammalian model of digit amputation. Tissue Eng A 2011;17(23-24):3033-44.
56. Choi YJ, Lee JY, Park JH, et al. The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials 2010; 31(28): 7226-38.
57. Damon DH. Endothelin and post-ganglionic sympathetic neurons. Clin Exp Pharmacol Physiol 1999; 26: 1000-3.
58. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN. Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003; 33(4): 673-84.
59. Azuma H, Kido J, Ikedo D, Kataoka M, Nagata T. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. J Periodontol 2004; 75: 974-81.
60. Goto T, Nakao K, Gunjigake KK, Kido MA, Kobayashi S, Tanaka T. Stimulation of late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 2007; 41: 25-31.
61. Wang L, Zhao R, Shi X, et al. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro. Bone 2009; 45(2): 309-20.
62. Hui Z, Yu L, Xiaoli Y, et al. C-terminal pentapeptide of osteogenic growth peptide regulates hematopoiesis in early stage. J Cell Biochem 2007; 101: 1423-9.
63. Chen Z, Wang X, Shao Y, et al. Synthetic osteogenic growth peptide promotes differentiation of human bone marrow mesenchymal stem cells to osteoblasts via RhoA/ROCK pathway. Mol Cell Biochem 2011; 358(1-2): 221-7.
64. Li G, Cui Y, McIlmurray L, Allen WE, Wang H. rhBMP-2, rhVEGF, rhPTN and thrombin-related peptide, TP508, induce chemotaxis of human osteoblasts and microvascular endothelial cells. J Orthop Res 2005; 23: 680-5.
65. Amir LR, Li G, Schoenmaker T, Everts V, Bronckers AL. Effect of thrombin peptide 508 (TP508) on bone healing during distraction osteogenesis in rabbit tibia. Cell Tissue Res 2007; 330(1): 35-44.
66. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-48.
67. Li W, Yu B, Li M, et al. NEMO-binding domain peptide promotes osteoblast differentiation impaired by tumor necrosis factor alpha. Biochem Biophys Res Commun 2010; 391(2): 1228-33.
68. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinasetype plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72(1): 1-22.
69. Geiger F, Lorenz H, Xu W, et al. VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute. Bone 2007; 41(4): 516-22.
70. Egusa H, Kaneda Y, Akashi Y, et al. Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts. Biomaterials 2009; 30(27): 4676-86.
71. Hamada Y, Egusa H, Kaneda Y, et al. Synthetic osteopontinderived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials. Dent Mater J 2007; 26(4): 487-92.
72. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved aminoterminal fragment of osteopontin. J Biol Chem 1999; 274(51): 36328-34.
73. Delany AM, Canalis E. Basic fibroblast growth factor destabilizes osteonectin mRNA in osteoblasts. Am J Physiol Cell Physiol 1998; 43(3): C734-40.
74. He X, Yang X, Jabbari E. Combined effect of osteopontin and bmp-2 derived peptides grafted to an adhesive hydrogel on osteogenic and vasculogenic differentiation of marrow stromal cells. Langmuir 2012; 28(12): 5387-97.
75. He X, Ma J, Jabbari E. Effect of grafting rgd and bmp-2 proteinderived peptides to a hydrogel substrate on osteogenic differentiation of marrow stromal cells. Langmuir 2008; 24(21): 12508-16.
76. Cacchioli A, Ravanetti F, Bagno A, Dettin M, Gabbi C. Human vitronectin-derived peptide covalently grafted onto titanium surface improves osteogenic activity: a pilot in vivo study on rabbits. Tissue Eng A 2009; 15(10): 2917-26.
77. Li JF, Lin ZY, Zheng QX, et al. Bone formation in ectopic and osteogenic tissue induced by a novel bmp-2-related peptide combined with rat tail collagen. Biotechnol Bioprocess Eng 2010; 15(5): 725-32.
78. Mercado AE, Jabbari E. Effect of encapsulation or grafting on release kinetics of recombinant human bone morphogenetic protein-2 from self-assembled poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Micros Res Tech 2010; 73: 824-33.
79. Mercado AE, He X, Xu WJ, Jabbari E. Release characteristics of a model protein from self-assembled succinimide-terminated poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Nanotechnology 2008; 19(32): 325609.
80. Reddi AH. BMPs: From bone morphogenetic proteins to body morphogenetic proteins. Cytokine Growth Factor Rev 2005; 16(3): 249-50.
81. Ai XB, Cappuzzello J, Hall AK. Activin and bone morphogenetic proteins induce calcitonin gene-related peptide in embryonic sensory neurons in vitro. Molecular Cellular Neurosci 1999; 14(6): 506-18.
82. Li QX, Kannan A, Wang W, et al. Bone morphogenetic protein 2 functions via a conserved signaling pathway involving Wnt4 to regulate uterine decidualization in the mouse and the human. J Biol Chem 2007; 282(43): 31725-32.
83. Aoyama K, Yamane A, Suga T, Suzuki E, Fukui T, Nakamura Y. Bone morphogenetic protein-2 functions as a negative regulator in the differentiation of myoblasts, but not as an inducer for the formations of cartilage and bone in mouse embryonic tongue. BMC Dev Biol 2011; 11: 44.
84. Cassar L, Li H, Pinto AR, Nicholls C, Bayne S, Liu JP. Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res 2000; 68(22): 9157-66.
85. Wetzel P, Haag J, Campean V, et al. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominently localized to the distal nephron. Kidney Internatl 2006; 70(4): 717-23.
86. Haaijman A, Karperien M, Lanske B, et al. Inhibition of terminal chondrocyte differentiation by bone morphogenetic protein 7 (OP-1) in vitro depends on the periarticular region but is independent of parathyroid hormone-related peptide. Bone 1999; 25(4): 397-404.
87. Wiley DM, Jin SW. Bone morphogenetic protein functions as a context-dependent angiogenic cue in vertebrates. Seminars Cell Dev Biol 2001; 22(9): 1012-8.
88. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006; 31(5): 542-7.
89. Cheng HW, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003; 85A(8): 1544-52.
90. Varghese S, Rydziel S, Canalis E. Bone morphogenetic protein-2 suppresses collagenase-3 promoter activity in osteoblasts through a runt domain factor 2 binding site. J Cell Physiol 2005; 202(2): 391-9.
91. Chan GK, Miao DS, Deckelbaum R, Bolivar I, Karaplis A, Goltzman D. Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T1/2 mesenchymal cells. Endocrinology 2003; 144(12): 5511-20.
92. Bramono DS, Murali S, Rai B, et al. Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2). Bone 2011; 50(4): 954-64.
93. Ratanavaraporn J, Tabata Y. Enhanced osteogenic activity of bone morphogenetic protein-2 by 2-O-desulfated heparin. Acta Biomater 2011; 8(1): 173-82.
94. Senta H, Bergeron E, Drevelle O, Park H, Faucheux N. Combination of synthetic peptides derived from bone morphogenetic proteins and biomaterials for medical applications. Can J Chem Eng 2011; 89(2): 227-39.
95. Schliephake H, Scharnweber D, Dard M, et al. Effect of RGD peptide coating of titanium implants on periimplant bone formation in the alveolar crest-An experimental pilot study in dogs. Clinical Oral Implants Res 2002; 13(3): 312-9.
96. Pallu S, Fricain JC, Bareille R, et al. Cyclo-DfKRG peptide modulates in vitro and in vivo behavior of human osteoprogenitor cells on titanium alloys. Acta Biomater 2009; 5(9): 3581-92.
97. Barber TA, Ho JE, De Ranieri A, Virdi AS, Sumner DR, Healy KE. Peri-implant bone formation and implant integration strength of peptide-modified p(AAm-co-EG/AAc) interpenetrating polymer network-coated titanium implants. JBiomed Mater Res A 2007; 80A(2): 306-320.
98. Lee JY, Choo JE, Park HJ, et al. Synthetic peptide-coated bone mineral for enhanced osteoblastic activation in vitro and in vivo. J Biomed Mater Res A 2008; 87A(3): 688-97.
99. Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Mineral Res 2004; 19(3): 455-62.
100. Hedberg EL, Kroese-Deutman HC, Shih CK, et al. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res A 2005; 72A(4): 343-53.
101. Lee JY, Choo JE, Choi YS, et al. Assembly of collagen-binding peptide with collagen as a bioactive scaffold for osteogenesis in vitro and in vivo. Biomaterials 2007; 28(29): 4257-67.
102. McGovern SC, Fong W, Wang JC. Can bone morphogenetic protein binding peptide increase efficiency of bone formation? Spine 2010; 35(17): 1655-9.